Compare Ascendis Pharma A/S (ASND) vs British American Tobacco PLC (BTI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs British American Tobacco PLC — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while British American Tobacco PLC trades at $59.09 (market cap $127.15B). The key difference: British American Tobacco PLC is far larger — about 7.2× Ascendis Pharma A/S's market cap, and British American Tobacco PLC pays a 5.56% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | BTI | |
|---|---|---|
Market Cap | $17.74B | $127.15B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $66.70 |
52-Week Low | $163.32 | $50.39 |
Enterprise Value | $18.11B | $168.38B |
Dividend Yield | — | 5.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
British American Tobacco (BTI) trades at $60.02, down 1.4% on the day, with a bearish technical signal from moving averages. The company shows strong profitability with a net income margin of 30.32% and a P/E ratio of 13.02, indicating potential undervaluation. Recent earnings have mostly beaten expectations, and the firm maintains a robust dividend, with two $0.83 payouts scheduled for H2 2026. However, 2023 saw a significant net loss, and 2025 cash flow is projected negative, highlighting volatility.
BTI offers a compelling value proposition with high margins and analyst support (66.7% buy ratings), but faces headwinds from regulatory pressures, declining cigarette volumes, and restructuring costs. The stock's outlook balances income appeal against sector-specific risks, requiring careful monitoring of its transition to smoke-free products and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →
